In the brains of people with Alzheimer's disease and other related disorders, the normally harmless protein called tau changes into a toxic form that damages nerve cells and impairs cognitive function. We have identified an enzyme that mediates the abnormal changes in tau protein. By inhibiting the activity of this enzyme, we can suppress neuronal cell death caused by tau. In this study, we aim to develop a fundamental treatment for dementia by developing a drug that targets this enzyme.